摘要
为了观察人参皂苷Rg3联合化疗对胃癌术后患者的临床疗效,将96例进展期胃癌术后患者随机分为治疗组(56例)和对照组(40例)。所有患者术后2周后行ELFP或EAP化疗,治疗组同时服用人参皂苷Rg3(参一胶囊)20mg,2次/d,均完成6个周期治疗。观察患者客观疗效、血清VEGF水平、CD3、CD4、CD4/CD8和T淋巴细胞转化率等免疫指标的变化。治疗组总有效率69.6%,明显高于对照组47.5%,P<0.05。治疗组患者治疗后血清VEGF平均下降39.5%(P<0.01),明显低于对照组治疗后血清VEGF水平,P<0.05。治疗组CD3、CD4、CD4/CD8、T淋巴细胞转化率均较治疗前有明显提高(P<0.05),而对照组上述指标均较治疗前有明显下降,P<0.05。初步研究结果提示,人参皂苷Rg3可通过抑制肿瘤新生血管形成、增强患者免疫力等途径提高化疗患者的疗效。
The objective of this study was to observe the effects of treatment on postoperative gastric cancer by ginsenoside Rg3 combined with chemotherapy.A total of 96 patients with advanced gastric cancer were randomly divided into treatment group（56 cases）and control group（40 cases）.All patients were treated with ELFP or EAP chemotherapy after 2 weeks of surgery.Patients in the treatment group took ginsenoside Rg3（shenyi capsules）20 mg,2 times a day.Six courses of treatment were completed.Objective efficacy,serum VEGF level and CD3,CD4,CD4/CD8,T lymphocyte transformation rate and other changes in immune parameters were observed in all patients.The total effective rate in the treatment group was 69.6%,significantly higher than 47.5% in the control group（P〈0.05）.Serum VEGF decreased 39.5% in patients of the treatment group after treatment（P〈0.01）,significantly lower than that in the control group after treatment（P〈0.05）.CD3,CD4,CD4/CD8 and T lymphocyte transformation rate in treatment group were significantly increased than that before treatment（P〈0.05）,while which were significantly decreased in the control group than that before treatment（P〈0.05）.In conclusion,ginsenoside Rg3 can improve the chemotherapy efficacy in patients with advanced gastric cancer,probably through inhibiting tumor angiogenesis and enhancing immune ability and so on.
出处
《中华肿瘤防治杂志》
CAS
2010年第10期779-781,共3页
Chinese Journal of Cancer Prevention and Treatment
